Kynteles is added in the revision of the domestic guidelines

The KASID, increased benefits by entering new drugs... Initiating revision of guidelines

Kynteles relieves concerns about systemic immunity with a specific mechanism that only works in the intestine

Kynteles is expected to be recommended as the first line therapy in the domestic IBD guidelines.

 

Kim Joo-sung, president of the KASID( Department of Gastroenterology, SNUH), guided domestically at a press conference to commemorate the expansion of insurance coverage for the first-line treatment of Inflammatory Bowel Disease (IBD) of Takeda's 'Kynteles (Vedolizumab)' held on the 12th.

 

Until now, in Korea, it had to be used secondarily only to patients who failed the TNF-α inhibitor according to the requirements.

 

However, as the indications were expanded as the first-line treatment at the beginning of this year and the reimbursement was obtained On the 1st, it can be used as a first-line treatment in Korea, regardless of using TNF-α inhibitors.

 

Kynteles, the only anti-integrin drug among the first-line treatments for IBD licensed in Korea, blocks inflammatory cells entering the intestine by a mechanism that specifically binds to α4β7 integrin of white blood cells that induce intestinal inflammation.

 

In other words, the risk of tuberculosis or infection is lower than that of conventional treatments because there is no confirmed systemic immune suppression effect and only works in the intestine.

 

Global guidelines also reflect this.

 

In February, the guidelines published by the American Gastrointestinal Association (AGA) suggested strategies for inducing remission in outpatients with moderate or severe ulcerative colitis, depending on whether or not treated with biological agents.

 

For patients without biologic treatment experience, conditional recommendations were given to Kynteles or Remicade (Infliximab) rather than Humira (Adalimumab) for remission induction.

 

Kim Joo-seong said, "The more available treatments, the more likely the medical staff will treat patients safely and effectively.

 

The domestic guidelines have also been revised.

 

As Kynteles can be prescribed with benefits for first-line therapy in Korea, This will be actively reflected in the new guidelines.

 

Meanwhile, Kynteles proved its effectiveness through a VARSITY study that directly compared with Humira.

 

According to the results of the study, the clinical remission† rate of patients treated with Kynteles was 31.3% at 52 weeks, and the clinical remission rate of Humira was 22.5%.

 

In addition, 39.7% of the patients treated with Kynteles showed the effect of healing the intestinal mucosa, whereas only 27.7% showed the effect in the control group.